# A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

> **NCT03694522** · PHASE2 · COMPLETED · sponsor: **Five Prime Therapeutics, Inc.** · enrollment: 155 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **BIOLOGICAL:** Bemarituzumab
- **DRUG:** Placebo
- **DRUG:** Modified FOLFOX6

## Key facts

- **NCT ID:** NCT03694522
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2020-09-23
- **Final completion:** 2022-05-13
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694522, "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03694522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*